Document |
Document Title |
WO/2000/042022A1 |
The invention provides compounds having formula (I), wherein W is OH, or derivatives of the carboxylic acid, and Q is a heterocyclo-condensed ortho-phenylene residue. These compounds are useful as MEK inhibitors, particularly in the trea...
|
WO/2000/039077A2 |
New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R¿1? is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R¿2? and R¿3? are the same o...
|
WO/2000/035885A1 |
Hydrazine derivatives of formula (I) wherein W represents O, S, CO, NR?5¿, (CR?3¿R?4¿)¿m?, or CR?11¿; X represents CO, NR?6¿, (CH¿2?)¿n?, CR?12¿ or CHR?13¿; Y represents CO, NR?7¿, (CH¿2?)¿p?, or CHR?14¿; Z represents CO, C...
|
WO/2000/036054A1 |
The invention relates to an active matrix display containing a chiral-smectic liquid crystal mixture which contains at least one compound of the formula (I) R?1¿-(A?1¿-M?1¿)¿a?-(A?2¿-M?2¿)¿b?-A?3¿-X-B?1¿-(B?2
¿)¿c?-R?2¿, in w...
|
WO/2000/035864A1 |
The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the tre...
|
WO/2000/034261A2 |
Compounds of formula (I) wherein R1-R5 are independently selected from hydrogen, or substituents R9-R12 are independently hydrogen, or substituents provided that at least one of R9-12 is not hydrogen; G is a monocyclic heteroaryl: X is a...
|
WO/2000/034237A2 |
Compounds of formula (I) wherein R¿1?-R¿5? are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to ...
|
WO/2000/034234A1 |
The present invention pertains to the field of medicine, more precisely to that of pharmacology, essentially relates to biologically active synthetic compounds of the heterocyclic series and is mainly intended for use in medical practice...
|
WO/2000/034259A1 |
The present invention pertains to the field of medicine, more precisely to that of pharmacology, and essentially relates to biologically active synthetic diazoles that consist of 2-R-5-amino-1,3,4-thiadiazole derivatives. These substance...
|
WO/2000/034258A2 |
Compounds having formula (I) wherein R¿1?-R¿5? are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3...
|
WO/2000/034268A1 |
Compounds of formula (I) wherein A is heteroaryl; R¿9?-R¿12? are independently hydrogen, alkyl of 1 to 4 carbon atoms, perhaloalkyl of 1 to 4 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, or cyano, or R¿9? and R¿10? or R¿11?...
|
WO/2000/032606A1 |
Cephem compounds represented by general formula (I) which have a broad antibacterial spectrum over various pathogenic bacteria and are also efficacious against MRSA, wherein X represents N or CY (wherein Y represents H or halogeno); R?1Â...
|
WO/2000/031074A2 |
A pharmaceutical compound of formula (I) in which R?1¿ and R?2¿ are each hydrogen, halo, cyano or methyl, the dotted line represents an optional double bond, X is (1) or (2), Y is (3) or (4) where R?4¿ and R?5¿ are each hydrogen, C¿...
|
WO/2000/029399A1 |
Disclosed herein are compounds of the general formula X-Aryl-Y-Z wherein X is a five or six-membered aromatic heterocycle attached to an Aryl group, for example a phenyl group; Y is absent or a bridging group, for example NHC(O)CH¿2?; a...
|
WO/2000/024725A1 |
The present invention relates to compounds which are useful in inhibiting the hepatitis C virus NS3 helicase. These compounds are useful in pharmaceutical compositions and method for treating and preventing HCV infection.
|
WO/2000/023416A1 |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (P...
|
WO/2000/023420A1 |
Compounds represented by formula (I), or salts thereof; a process for the preparation thereof; and somatostatin receptor regulators containing the compounds or salts: wherein A is an optionally substituted aromatic ring; B is an optional...
|
WO/2000/023430A1 |
The invention relates to compounds of formula (I) which are used to produce drugs for prophylaxis and therapy of all conditions whose development is associated to an increased level of interleukin-1$g(b), e.g. septic shock, leukaemia, he...
|
WO/2000/023421A1 |
This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in t...
|
WO/2000/021920A1 |
Compounds of the formula (1a), wherein R1 is a group of the formula (2) where R1, R2, A, B, U, V, W, X, Y, Z, k and n have the significance given in the specification, are useful to treat rheumatoid arthritis, psoriasis, multiple scleros...
|
WO/2000/020415A1 |
The invention relates to novel phenylacetic acid heterocyclyl amides of formula (I) in which R?1¿, R?2¿, R?3¿, R?4¿, A, X and n have the meanings cited in the description. The invention also relates to a method for producing these no...
|
WO/2000/020371A1 |
Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed. The compounds are represented by formula (II): Ar?1¿-W-Ar?2¿-X-Q. The compounds of the invention are str...
|
WO/2000/017159A1 |
The invention provides compounds, compositions and methods relating to arylsulfonanilide derivatives having the formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar is a member selected from the group consisting of (a), ...
|
WO/2000/015232A1 |
A method for the treatment of infectious gastrointestinal ulcer disease or infectious gastritis disease of microbially infected gastrointestinal tissue in a mammal involves administration of an antimicrobial amount of an antimicrobial me...
|
WO/2000/012084A1 |
The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treat...
|
WO/2000/012082A1 |
A family of compounds having general structural formula (I) where W is a reverse hydroxamic acid group, and R¿1?, R¿2?, R¿3?, R¿4?, R¿5? and R¿6? are as described in the specification, or a pharmaceutically acceptable salt, solvate...
|
WO/2000/010969A1 |
Novel sulfonylimide and sulfonylmethide compounds are described which are useful as conductive salts. Also described is the use of the above compounds in salt form in battery electrolytes, particular salts having mixed perfluorocarbon an...
|
WO/2000/011121A1 |
A reaction product obtained by reacting a sulphurized olefin with a thiadiazole derivative. The reaction product may be used in a lubricant as an antioxidant, a copper passivator and/or an extreme pressure additive.
|
WO/2000/009115A1 |
Novel GRP receptor antagonists are provided. Methods of using the present compounds to antagonize GRP receptors are also provided. The present invention further involves the synthesis of the present compounds.
|
WO/2000/009116A1 |
Novel GRP receptor antagonists are provided. Methods of using the present compounds to antagonize GRP receptors are also provided. The present invention further involves the synthesis of the present compounds.
|
WO/2000/006538A1 |
Provided are methods of purification of an organic lithium salt comprising the steps of: (a) dissolving an impure organic lithium salt in a solution comprising an organic complexing solvent; (b) crystallizing from said solution a solid s...
|
WO/2000/004898A1 |
Combinations of a prostaglandin, prostaglandin derivative, a hypotensive lipid derived from a prostaglandin or prostaglandin derivative or an ophthalmologically acceptable salt thereof, a $g(b)-adrenergic antagonist or an ophthalmologica...
|
WO/2000/005221A1 |
The invention relates to substituted benzoylcyclohexandiones of general formula (I), wherein A represents a single bond or alkane diyl (alkene) and Z represents an optionally substituted 4-12 membered, saturated on unsaturated, monocylic...
|
WO/2000/001376A2 |
New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of demyelinating disorders. Inhibitors of the interaction of glutamate with the AMPA and/or kainate receptor complex are likely to be us...
|
WO/2000/000465A1 |
The invention provides hydrazine derivatives of formula (I) wherein R?1¿ is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R?2¿ is an acyl group derived from an $g(a)-, $g(b)-, $g(...
|
WO/1999/067231A1 |
Nitric acid salts with medicines having an antihypertensive activity.
|
WO/1999/065886A1 |
Benzazole compounds of formula (I) wherein R¿1?, R¿2?, R¿3?, R¿4?, X, Y and Z have the significances given in claim 1, may be used as insect-, mite- and tick-repellent compositions and can be produced in known manner.
|
WO/1999/065922A2 |
A family of compounds capable of inhibiting the activity of prenyl transferases. The compounds are covered by five formulas (I), (II), (III), (IV), (V). Each of the R groups is defined in the disclosure.
|
WO/1999/065871A2 |
This invention pertains to the discovery of a novel family of thiolesters and uses thereof. Also provided for are viricidal compounds and pharmaceutical formulations comprising these novel thiolesters. The invention also provides thioles...
|
WO/1999/062968A1 |
Methods for preparing olefin polymers, and catalysts for preparing olefin polymers are disclosed. The polymers can be prepared by contacting the corresponding monomers with a Group 8-10 transition metal catalyst and a solid support. The ...
|
WO/1999/062506A1 |
The use of compounds of formula (I), and salts thereof; and pharmaceutically acceptable $i(in vivo) cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs; in formula (...
|
WO/1999/061416A1 |
The invention concerns substituted dithio-bis-nitrobenzenes (dithio-bis-nitrobenzylamines, dithio-bis-nitrobenzamides or dithio-bis-nitrophenacyls) and their uses as alternative substrates for NAD(P)H-dependent disulphide-reductase enzym...
|
WO/1999/055665A1 |
The invention relates to novel azines, to a method for producing said azines and to their use as fungicides.
|
WO/1999/052874A1 |
Difluoroalkene derivatives represented by formula (1) wherein m is an integer of 3 to 14; n is an integer of 0 to 2; and Q represents an optionally substituted, specific heteroaromatic ring; and an agricultural or horticultural pest cont...
|
WO/1999/052882A1 |
1,2,3-thiadiazole derivative represented by general formula (I): wherein either R¿1? or R¿2? is -W-CH¿2?-CH¿2?-C(X)=CF¿2? wherein W is -O-, -S(O)¿n?- where n is 0 to 2, -C(=Z)-Y- wherein Z is O or S, Y is O, S, NR¿3? where R¿3? i...
|
WO/1999/051584A1 |
Novel 3,5-disubstituted 1,2,4-thiadiazole compounds are provided, which are effective in treating peptic ulcers by the inhibition of H?+¿/K?+¿-ATPase. The compounds of the present invention are 3,5-disubstituted 1,2,4-thiadiazole corre...
|
WO/1999/049856A2 |
Compounds of the general structure D-L-B-(AA), for example (A), that are useful for treating Mac-1 or LFA-1-mediated disorders such as inflammatory disorders, allergies, and autoimmune diseases are provided.
|
WO/1999/047508A1 |
Compounds of formula (I), pharmaceutically acceptable salts or $i(in vivo) hydrolysable esters thereof, wherein: Ring X is phenyl or a six membered heteroaryl ring containing one or two ring nitrogens where said nitrogens are optionally ...
|
WO/1999/047520A1 |
A process for the production of a compound of formula (I), wherein R¿1? is hydrogen or C¿1?-C¿4?-alkyl; R¿2? is hydrogen, C¿1?-C¿6?-alkyl, C¿2?-C¿6?-alkenyl, C¿2?-C¿6?-alkinyl, C¿3?-C¿6?-cycloalkyl or a radical -CH¿2?B; A is...
|
WO/1999/047507A2 |
The present invention presents novel 1,3,4-thiadiazole derivatives of formula (I) which have useful antiviral activity against herpes virus, cytomegalovirus (CMV).
|